{"nctId":"NCT05082116","briefTitle":"Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)","startDateStruct":{"date":"2021-09-27","type":"ACTUAL"},"conditions":["Haemophilia A"],"count":36,"armGroups":[{"label":"N8-GP prophylaxis","type":"EXPERIMENTAL","interventionNames":["Drug: turoctocog alfa pegol (N8-GP)"]}],"interventions":[{"name":"turoctocog alfa pegol (N8-GP)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.\n* Male Chinese patient with severe congenital haemophilia A with a FVIII activity below 1% according to medical records.\n* Aged greater than or equal to 12 years at the time of signing informed consent.\n* History of at least 150 exposure days (EDs) to other FVIII products.\n* The patient and/or caregiver is capable of assessing a bleeding episode, keeping a diary, performing home treatment of bleeding episodes and otherwise following the trial procedures at the discretion of the investigator.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to trial product or related products.\n* Previous participation in this trial. Participation is defined as signed informed consent.\n* Participation in any clinical trial of an approved or non-approved investigational medicinal product within 5 half-lives or 30 days from screening, whichever is longer.\n* Known history of FVIII inhibitors based on existing medical records, laboratory report reviews and patient and/or caregiver interviews.\n* Current FVIII inhibitors greater than or equal to 0.6 BU.\n* Congenital or acquired coagulation disorder other than haemophilia According to medical records.\n* HIV positive, defined by medical records, with CD4+ count less than or equal 200/L and a viral load greater than 200 particles/μl or greater than 400000 copies/mL within 6 months of the trial entry. If the data are not available in medical records within last 6 months, then the test must be performed at screening visit.\n* Previous significant thromboembolic events (e.g. myocardial infarction, cerebrovascular disease or deep venous thrombosis) as defined by available medical records.\n* Hepatic dysfunction defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) greater than 3 times limit of normal combined with total bilirubin greater than 1.5 times the upper limit of normal at screening, as defined by central laboratory\n* Renal impairment defined as estimated glomerular filtration rate (eGFR) below or equal to 30 mL/min/1.73 m\\^2 for serum creatinine measured at screening, as defined by central laboratory.\n* Platelet count below 50×109/L at screening based on central laboratory values at screening.\n* Ongoing immune modulating or chemotherapeutic medication.\n* Any disorder, except for conditions associated with haemophilia A, which in the investigator's opinion might jeopardise the patient's safety or compliance with the protocol.\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.","healthyVolunteers":false,"sex":"MALE","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Bleeding Episodes Per Year (Annualised Bleeding Rate)","description":"Number of bleeding episodes per year (Annualised Bleeding Rate) data is reported. Annualised bleeding rate (ABR) is the number of bleeding episodes per year.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemostatic Effect of N8-GP When Used for Treatment of Bleeding Episodes, Assessed on a Four-point Scale for Haemostatic Response (Excellent, Good, Moderate and None)","description":"Haemostatic effect of N8-GP for treatment of bleeding episodes was assessed by 4-point response scale: none, moderate, good or excellent. Evaluation during trial was done by participant and/or parent(s)/caregiver within approximately 8 hours after a single injection as follows: Excellent: Abrupt pain relief and/or clear improvement in objective signs of bleeding within approximately 8 hrs after a single injection; Good: Definite pain relief and/or improvement in signs of bleeding within approximately 8 hrs after a single injection, but possibly requiring more than one injection for complete resolution; Moderate: Probable or slight beneficial effect within approximately 8 hours after the first injection, but usually requiring more than one injection; None: No improvement, or worsening of symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Injections Needed to Treat Bleeding Episodes","description":"The mean number of injections of N8-GP used for treatment of a bleed from start to stop of a bleed was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"0.8"},{"groupId":"OG001","value":"1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Consumption of N8-GP for Prophylaxis","description":"The mean consumption of N8-GP for prophylaxis per year per participant was reported and it was measured in international units per kilogram per year (IU/kg/year).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4909.5","spread":"252.0"},{"groupId":"OG001","value":"4873.9","spread":"237.6"}]}]}]},{"type":"SECONDARY","title":"FVIII Trough Activity During Prophylaxis","description":"Trough levels of FVIII was reported for all participnats who received prophylaxis treatment. Chromogenic assay was performed with N8-GP product specific standard (PSS) as a calibrator. The analysis is based on a mixed model on the log transformed plasma FVIII activity with age group as fixed effect and participant as a random effect. The mean trough is presented back-transformed to the natural scale.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.032","spread":null},{"groupId":"OG001","value":"0.034","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Incidence Rate of Confirmed FVIII Inhibitors ≥0.6 BU","description":"Percentage of participants who developed inhibitory antibodies against FVIII was presented. A participant was said to have FVIII-inhibitors if two consecutive tests, preferably within 2 weeks, were positive (greater than or equal to (≥) 0.6 bethesda unit (BU)). For the calculation of the inhibitor rate the numerator was included for all participants with neutralising antibodies while the denominator was included for all participants with a minimum of 50 exposures plus any participants with less than 50 exposures but with neutralising inhibitor.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events (AEs)","description":"An adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All presented AEs are treatment-emergent. A treatment-emergent adverse event was defined as an event with onset after first N8-GP administration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events (SAEs)","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, or is life-threatening, or requires inpatient hospitalization or causes prolongation of existing hospitalization results in persistent or significant disability/incapacity, or may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage. All presented SAEs are treatment-emergent (any serious adverse events which occurred after trial product administration).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incremental Recovery (IR)","description":"The incremental recovery was calculated by subtracting the FVIII activity (IU/mL) measured in plasma at time 0 from that measured at time 30 min after dosing and dividing this difference by the dose injected at time 0 expressed as IU/kg body weight. FVIII activity was measured with a chromogenic assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.023","spread":"28.107"},{"groupId":"OG001","value":"0.023","spread":"28.367"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.029","spread":"1.443"},{"groupId":"OG001","value":"0.024","spread":"23.535"}]}]}]},{"type":"SECONDARY","title":"FVIII Activity 30 Min Post-injection (C30min)","description":"FVIII plasma activity was measured after 30 mins of injection. FVIII activity was measured with a chromogenic assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.178","spread":"24.531"},{"groupId":"OG001","value":"1.196","spread":"27.304"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.557","spread":"0.646"},{"groupId":"OG001","value":"1.302","spread":"21.521"}]}]}]},{"type":"SECONDARY","title":"FVIII Trough Activity 96 h Post-injection (C96h)","description":"FVIII plasma activity was measured after 96 h of injection. This was measured at two time points Week 0 and Week 28 during the study. Chromogenic assay was performed.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.033","spread":"36.048"},{"groupId":"OG001","value":"0.039","spread":"44.608"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.032","spread":"14.616"},{"groupId":"OG001","value":"0.045","spread":"58.020"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (AUC0-inf)","description":"Area under the plasma activity versus time profile from time zero to infinity (AUC0-inf) was measured.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.556","spread":"20.100"},{"groupId":"OG001","value":"33.650","spread":"26.123"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.274","spread":"4.541"},{"groupId":"OG001","value":"37.952","spread":"28.030"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (0-t)","description":"Area under the plasma activity versus time profile from time zero to last measurable activity (AUC0-t) was measured.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.578","spread":"19.999"},{"groupId":"OG001","value":"32.300","spread":"26.565"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.467","spread":"4.292"},{"groupId":"OG001","value":"36.406","spread":"27.173"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve (0-96h)","description":"Area under the plasma activity versus time profile from time zero to 96 hours (AUC0-96h) was measured.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.509","spread":"19.989"},{"groupId":"OG001","value":"32.269","spread":"26.558"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.428","spread":"4.251"},{"groupId":"OG001","value":"36.398","spread":"27.168"}]}]}]},{"type":"SECONDARY","title":"Accumulation Ratio","description":"Accumulation ratio was calculated as AUC(0-96h) at steady state/AUC(0-96h) at single dose. AUC(0-96) is the area under the plasma activity versus time profile from time zero to 96 hours.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.152","spread":"19.682"},{"groupId":"OG001","value":"1.086","spread":"53.085"}]}]}]},{"type":"SECONDARY","title":"Terminal Half-life (t½)","description":"Terminal half life was calculated as ln(2)/λz; where λz is the terminal elimination rate constant. The terminal elimination rate constant was estimated using linear regression on the terminal part of the log (activity) versus time profile.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.106","spread":"14.019"},{"groupId":"OG001","value":"20.200","spread":"20.422"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.729","spread":"5.568"},{"groupId":"OG001","value":"20.238","spread":"18.882"}]}]}]},{"type":"SECONDARY","title":"Clearance (CL)","description":"Clearance (CL) of drug after intravenous administration was reported. Clearance was calculated using the formula CL= Dose / AUC(0-inf) for single dose and CL= Dose / AUC(0-96) h for steady state.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.636","spread":"17.092"},{"groupId":"OG001","value":"1.550","spread":"29.123"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.434","spread":"4.488"},{"groupId":"OG001","value":"1.434","spread":"25.335"}]}]}]},{"type":"SECONDARY","title":"Apparent Volume of Distribution (Vz) Based on the Terminal Phase","description":"Apparent volume of distribution (Vz) based on the terminal phase was measured. Apparent volume of distribution was calculated using formula: total plasma clearance divided by terminal elimination rate constant (Vz= CL/λz).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.098","spread":"24.375"},{"groupId":"OG001","value":"45.165","spread":"34.649"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.673","spread":"4.042"},{"groupId":"OG001","value":"41.878","spread":"27.534"}]}]}]},{"type":"SECONDARY","title":"Apparent Volume of Distribution (Vss) Based on Steady-state","description":"Apparent volume of distribution (Vss) at steady-state was measured. Apparent volume of distribution (Vss) was calculated using formula: total plasma clearance multiplied by mean residence time (Vss=CL\\*MRT).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.511","spread":"5.727"},{"groupId":"OG001","value":"39.786","spread":"28.558"}]}]}]},{"type":"SECONDARY","title":"Extrapolated Area Under the Curve (AUC Percent [%] Extrap","description":"Percentage of AUC(0-inf) determined by extrapolation. It was calulating using formula: Area under the plasma activity versus time profile from given measurable time to infinity (AUCt-inf)/Area under the plasma activity versus time profile from time zero to infinity (AUC0-inf).","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.847","spread":"47.917"},{"groupId":"OG001","value":"3.392","spread":"63.420"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.143","spread":"17.743"},{"groupId":"OG001","value":"3.424","spread":"65.849"}]}]}]},{"type":"SECONDARY","title":"Mean Residence Time","description":"Mean residence time (MRT) calculated as area under the first moment plasma concentration-time curve (AUMC \\[0-inf\\]) divided by AUC (0-inf). (AUMC \\[0-inf\\]) is the area under the first moment plasma concentration-time curve from time 0 to infinity.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.101","spread":"13.400"},{"groupId":"OG001","value":"27.941","spread":"21.114"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.070","spread":"4.347"},{"groupId":"OG001","value":"27.739","spread":"22.177"}]}]}]},{"type":"SECONDARY","title":"Terminal Elimination Rate Constant (λz)","description":"The terminal elimination rate constant was estimated using linear regression on the terminal part of the log(activity) versus time profile.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.036","spread":"13.526"},{"groupId":"OG001","value":"0.034","spread":"18.083"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.039","spread":"5.749"},{"groupId":"OG001","value":"0.034","spread":"16.862"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Weight decreased","Hyperuricaemia","Pyrexia","Upper respiratory tract infection","Abdominal discomfort"]}}}